PDL BIOPHARMA, INC. 4
4 · PDL BIOPHARMA, INC. · Filed Jan 30, 2015
Insider Transaction Report
Form 4
Stone Christopher Lewis
VP and General Counsel
Transactions
- Award
Common stock
2015-01-28$7.62/sh+33,110$252,298→ 140,473 total
Footnotes (1)
- [F1]The restricted stock will vest, provided that the officer remains employed by the Company and certain performance goals are achieved, based upon the following schedule: 50% on December 2016; 16.66% on January 2017; 16.66% on January 2018; and 16.66% on January 2019.